pcac-july-multi-peptide
pcac-july-multi-peptide
The prediction
At least 2 of the 4 peptides reviewed at the 2026-07-23 PCAC meeting (BPC-157, KPV, MOTs-C, TB-500) receive a Category 1 or conditional Category 1 recommendation
REVISION to prior forecast. 12-peptide Cat 2 removal wave Apr 15 is a much more aggressive reclassification trajectory than anticipated. Original 0.70 not-Cat-1 forecast for BPC-157 alone still holds, but broadened basket (any 2 of 4) makes at-least-one-Cat-1 meaningfully more likely. Counter-narrative ~45%: safety dossiers still weak for all four; PCAC defers to additional review session. Compounding pharmacy lobby organized but without FDA-approvable safety data, caution wins.
Trajectory
- 19 April 2026 · created55%signal strength 68
REVISION to prior forecast. 12-peptide Cat 2 removal wave Apr 15 is a much more aggressive reclassification trajectory than anticipated. Original 0.70 not-Cat-1 forecast for BPC-157 alone still holds, but broadened basket (any 2 of 4) makes at-least-one-Cat-1 meaningfully more likely. Counter-narrative ~45%: safety dossiers still weak for all four; PCAC defers to additional review session. Compounding pharmacy lobby organized but without FDA-approvable safety data, caution wins.
- 2026-04-19 07:00 UTC · Ra run52%-0.03· signal 66
No material new evidence today. Skeptic's falsifier (USP monograph progress) is absent rather than present which slightly weakens the Cat 1 case. Bayesian posterior 0.52.
Counter-narrativeFDA 12-peptide Cat 2 removal wave suggests willingness to move to Cat 1 without USP monograph; if so the prior is too conservative
- 2026-04-22 04:04 UTC · Ra runread brief →58%+0.06· signal 72
12-peptide Cat 2 removal wave + RFK public commitment + conveyor-belt scheduling (July 23-24 + Feb 2027 follow-up) collectively raise probability. Historian draws DSHEA analogy: once political momentum shifts, batch reclassification accelerates. Augur notes conveyor-belt institutional momentum. But Skeptic correctly identifies batch-defer scenario as live counter-case.
Counter-narrativeSafety dossiers remain weak for all four peptides; PCAC could defer entire batch if career scientists resist political pressure
- 2026-04-22 10:52 UTC · Ra runread brief →60%+0.02· signal 73
Second-pass council (10:52 UTC). RAPS/BioSpace confirm batch review framing. Superseded by 15:30 run with STAT/PCAC vacancy signal.
Counter-narrativePCAC defers all four peptides citing inadequate safety data; batch-defer scenario remains live
- 2026-04-22 15:30 UTC · Ra runread brief →62%+0.04· signal 74
PCAC vacancy mechanism + STAT reporting strengthen the at-least-2-of-4 thesis. DSHEA 1994 analogy: batch reclassification accelerates under political momentum. Even if panel passes only BPC-157 and TB-500, that satisfies the threshold. Blanket deferral is the live counter-case but unlikely given appointment dynamics.
Counter-narrativeAll four peptides lack adequate safety dossiers; PCAC defers entire batch or career scientists override political pressure in a blanket deferral
- 2026-04-23 07:04 UTC · Ra runread brief →62%0· signal 74
PCAC agenda expanded to 7 peptides across 2 days. Day 1 basket of 4 unchanged. Two-day marathon suggests substantive deliberation not rubber stamp. Holding.
Counter-narrativeCareer scientists use Day 1 batch scope to argue for blanket deferral pending safety dossier completion
- 2026-04-24 07:04 UTC · Ra runread brief →62%0· signal 74
Same legal analysis applies. Day 1 basket of 4 unchanged. Two-day PCAC marathon suggests substantive deliberation. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers for all four peptides
- 2026-04-25 07:04 UTC · Ra runread brief →62%0· signal 74
Same legal analysis applies. Public comment window July 9-22 is the next signal-rich period. Industry coalition letters expected early July. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers for all four peptides
- 2026-04-26 07:04 UTC · Ra runread brief →62%0· signal 74
88 days to PCAC. No new signals beyond confirmed vacancy mechanism. Public comment docket open. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers for all four peptides
- 2026-04-27 07:04 UTC · Ra runread brief →62%0· signal 74
Weekly review: 7 peptides across 2-day agenda. Day 1 basket of 4 unchanged. Two-day marathon and Feb 2027 follow-up session create conveyor-belt institutional momentum. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- https://www.fiercepharma.com/pharma/fda-advisory-committee-set-weigh-taking-action-certain-unapproved-peptides
- 2026-04-28 04:04 UTC · Ra runread brief →62%0· signal 74
86 days to PCAC. Seven peptides across 2-day agenda. No vacancy appointment signals. Public comment window July 9-22 approaching. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers for all four peptides
- 2026-04-29 07:04 UTC · Ra runread brief →62%0· signal 74
85 days to PCAC. Same vacancy dynamics apply. Public comment docket open. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- 2026-04-30 07:04 UTC · Ra runread brief →62%0· signal 74
84 days to PCAC. Legal analysis confirms PCAC is advisory only; FDA rulemaking required after recommendation. Public comment docket open. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers for all four peptides
- 2026-05-01 07:04 UTC · Ra runread brief →60%-0.02· signal 72
PCAC roster confirmed: 3 voting members + 1 industry liaison + no chair vs 12 authorized. Kennedy filled ACIP Feb 27 but not PCAC. Dysfunctional committee increases deferral probability. Day 2 agenda (DSIP, Semax, Epitalon) confirms substantive 2-day deliberation. -0.02.
Counter-narrativeKennedy fills PCAC vacancies with pro-access appointees creating supermajority for batch Cat 1; or 3-member committee yields high-variance vote in either direction
- https://www.hhs.gov/press-room/secretary-kennedy-appoints-two-physicians-cdc-advisory-committee.html
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-05-02 07:04 UTC · Ra runread brief →60%0· signal 74
FDA simultaneously cracking down on GLP-1 compounding while considering opening peptide compounding — institutional tension could support managed-transition thesis. Net: no material movement. 82 days to PCAC. Holding.
Counter-narrativeKennedy fills PCAC vacancies creating supermajority for batch Cat 1; or 503B GLP-1 crackdown creates reform-not-ban narrative favoring peptide reclassification
- 2026-05-03 07:04 UTC · Ra runread brief →60%0· signal 74
81 days to PCAC. Same vacancy dynamics. Public comment deadline July 9. No USP monograph progress. No new safety dossier submissions. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers for all four peptides
- 2026-05-04 07:04 UTC · Ra runread brief →58%-0.02· signal 72
PCAC renewal to 2028 confirms institutional structure. Binary outcome risk: batch reviews tend toward consistent standard (all Cat 1 or all deferred) rather than 2-of-4 split. 3-member committee high variance. Accumulating dysfunction signal warrants modest -0.02.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers; dysfunctional 3-member committee without chair increases deferral probability
- 2026-05-05 07:04 UTC · Ra runread brief →58%0· signal 72
79 days to PCAC. Per-peptide evaluation confirmed supports differentiation thesis but 3-member committee high variance. Oral presentation deadline June 30. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral; or Kennedy fills vacancies creating pro-access majority
- 2026-05-06 07:04 UTC · Ra runread brief →58%0· signal 72
78 days to PCAC. No new safety dossier submissions or USP monograph progress. Oral presentation deadline June 30 is next signal-rich window. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers for all four peptides
- 2026-05-07 07:04 UTC · Ra runread brief →58%0· signal 72
77 days to PCAC. Same vacancy dynamics. No USP monograph progress. No safety dossier submissions. Oral presentation deadline June 30 is next signal-rich window. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers for all four peptides
- 2026-05-08 07:04 UTC · Ra runread brief →58%0· signal 72
76 days to PCAC. HealingMaps reports 7 peptides on July agenda — need to verify whether all 4 tracked peptides (BPC-157 KPV MOTS-c TB-500) confirmed for July 23-24 vs deferred to Feb 2027. Larger agenda may favor blanket outcomes over differentiated per-peptide decisions. Holding.
Counter-narrativeCareer scientists use batch scope to argue for blanket deferral citing inadequate safety dossiers for all four peptides
- 2026-05-09 07:04 UTC · Ra runread brief →58%0· signal 72
75 days to PCAC. FDA confirms all 4 tracked peptides on Day 1 July 23 — Day 2 reserved for DSIP Semax Epitalon. Per-peptide differentiation framework reaffirmed. Foley clarification on Cat 2 removal ≠ Cat 1 grant slightly raises bar. Holding.
Counter-narrativeCareer scientists use Day 1 batch scope to argue for blanket deferral citing inadequate safety dossiers across all four peptides
- 2026-05-10 07:04 UTC · Ra runread brief →58%0· signal 72
74 days to PCAC. All 4 tracked peptides confirmed Day 1 July 23. Per-peptide differentiation supports mid-range probability. No USP monograph progress. Holding.
Counter-narrativeCareer scientists use Day 1 batch scope to argue for blanket deferral citing inadequate safety dossiers
- 2026-05-11 07:04 UTC · Ra runread brief →58%0· signal 72
73 days to PCAC. All 4 tracked peptides confirmed Day 1 July 23. Binary outcome heuristic continues. No new USP monograph progress. Holding.
Counter-narrativeCareer scientists use Day 1 batch scope to argue for blanket deferral citing inadequate safety dossiers across all four peptides
- 2026-05-12 07:04 UTC · Ra runread brief →58%0· signal 72
72 days to PCAC. Hims call reinforces market attention but does not change safety-dossier dynamics. No USP monograph progress. Holding.
Counter-narrativeCareer scientists use Day 1 batch scope to argue for blanket deferral citing inadequate safety dossiers across all four peptides
- 2026-05-13 07:04 UTC · Ra runread brief →58%0· signal 72
71 days to PCAC. Two-day meeting covering 7 peptides. $300B peptide wellness market report (GlobeNewsWire May 12) is discourse-infrastructure signal for lobbying intensity. No USP monograph progress. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda to argue for blanket deferral citing inadequate safety dossiers
- 2026-05-14 07:04 UTC · Ra runread brief →58%0· signal 72
70 days to PCAC. No USP monograph progress. $300B market report still the latest discourse-infrastructure signal. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda to argue for blanket deferral citing inadequate safety dossiers
- 2026-05-15 07:04 UTC · Ra runread brief →58%0· signal 72
69 days to PCAC. Olympia Pharmaceuticals confirms Cat 2 removal does not confer Cat 1 automatically — individual PCAC review required. No USP monograph progress. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda to argue for blanket deferral citing inadequate safety dossiers
- 2026-05-16 07:04 UTC · Ra runread brief →58%0· signal 72
68 days. Federal Register confirms 4-peptide agenda July 23 + additional peptides July 24 reinforcing crowded-agenda deferral risk. No USP monograph progress for any of four. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda to argue for blanket deferral citing inadequate safety dossiers
- https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-05-17 07:04 UTC · Ra runread brief →58%0· signal 68
Agenda confirmed: 4 tracked peptides Day 1, 3 more Day 2 per HealingMaps. No USP monograph progress. Holding.
Counter-narrativeCrowded 7-peptide agenda raises per-peptide deferral risk; USP monograph progress remains absent for all 4 tracked peptides
- 2026-05-18 07:04 UTC · Ra runread brief →58%0· signal 68
66 days. NatLawReview reinforces procedural gap between Cat 2 removal and Cat 1 conferral. No USP monograph progress for any of four tracked peptides. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda to argue for blanket deferral citing inadequate safety dossiers
- https://natlawreview.com/article/tiny-chains-big-changes-what-fdas-latest-actions-mean-peptide-compounding
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-05-19 07:04 UTC · Ra runread brief →58%0· signal 68
65 days. Foley & Lardner confirms Cat 2 removal does not confer Cat 1. No USP monograph progress for any of four tracked peptides. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda to argue for blanket deferral citing inadequate safety dossiers
- 2026-05-20 07:04 UTC · Ra runread brief →58%0· signal 72
64 days to PCAC. No USP monograph progress for any of four tracked peptides. Oral presentation deadline June 30 is next signal-rich window. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda to argue for blanket deferral citing inadequate safety dossiers
- 2026-05-21 07:04 UTC · Ra runread brief →57%-0.01· signal 72
63 days to PCAC. Same quorum dynamics. 4-member committee reviewing 7 peptides over 2 days is institutional-capacity constraint favoring binary outcomes over per-peptide differentiation — makes at-least-2-of-4 threshold harder. -0.01.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda plus understaffed 4-member committee to argue for blanket deferral; Kennedy batch-fills could flip to batch Cat 1
- https://natlawreview.com/article/tiny-chains-big-changes-what-fdas-latest-actions-mean-peptide-compounding
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- 2026-05-22 07:04 UTC · Ra runread brief →57%0· signal 72
62 days to PCAC. Same quorum dynamics. No USP monograph progress. Oral presentation deadline June 30 is next signal-rich window. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda plus understaffed 4-member committee to argue for blanket deferral; Kennedy batch-fills could flip to batch Cat 1
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- https://lengealaw.com/fda-puts-bpc-157-tb-500-and-5-other-peptides-under-the-microscope-what-prescribers-need-to-know-about-the-503a-review/
- 2026-05-23 07:04 UTC · Ra runread brief →57%0· signal 72
61 days to PCAC. Same quorum dynamics. No USP monograph progress. Oral presentation deadline June 30 is next signal-rich window. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda plus understaffed 4-member committee to argue for blanket deferral; Kennedy batch-fills could flip to batch Cat 1
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-05-24 07:04 UTC · Ra runread brief →57%0· signal 72
60 days to PCAC. Same quorum dynamics. No USP monograph progress. Oral presentation deadline June 30 is next signal-rich window. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda plus understaffed 4-member committee to argue for blanket deferral; Kennedy batch-fills could flip to batch Cat 1
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-05-26 07:04 UTC · Ra runread brief →57%0· signal 72
58 days to PCAC. Same quorum dynamics. No USP monograph progress. 4-member committee reviewing 7 peptides over 2 days favors binary outcomes over per-peptide differentiation. Oral presentation deadline June 30 is next signal-rich window. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda plus understaffed 4-member committee to argue for blanket deferral; Kennedy batch-fills could flip to batch Cat 1
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-05-27 07:04 UTC · Ra runread brief →57%0· signal 72
57 days to PCAC. Same quorum dynamics. No USP monograph progress. Oral presentation deadline June 30 is next signal-rich window — 34 days. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda plus understaffed 4-member committee to argue for blanket deferral; Kennedy batch-fills could flip to batch Cat 1
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-05-28 07:04 UTC · Ra runread brief →57%0· signal 72
56 days to PCAC. Same quorum dynamics. No USP monograph progress. Oral presentation deadline June 30 is next signal-rich window — 33 days. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda plus understaffed 4-member committee to argue for blanket deferral; Kennedy batch-fills could flip to batch Cat 1
- 2026-05-29 07:04 UTC · Ra runread brief →57%0· signal 72
55 days to PCAC. Same quorum dynamics. No USP monograph progress. Oral presentation deadline June 30 is next signal-rich window — 32 days. 4-member committee reviewing 7 peptides favors binary outcomes. Holding.
Counter-narrativeCareer scientists use crowded 7-peptide two-day agenda plus understaffed 4-member committee to argue for blanket deferral; Kennedy batch-fills could flip to batch Cat 1
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-05-30 07:04 UTC · Ra runread brief →57%0· signal 72
54 days to PCAC. ACIP FACA ruling constrains unqualified batch-fill but existing 3-member committee could still vote favorably. Oral presentation deadline June 30 in 31 days. No USP monograph progress.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.apha.org/news-and-media/news-releases/apha-news-releases/federal-judge-blocks-immunization-schedule-changes
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.federalregister.gov/documents/2026/05/29/2026-10674/advisory-committee-psychopharmacologic-drugs-advisory-committee-renewal
- 2026-05-31 07:04 UTC · Ra runread brief →57%0· signal 72
53 days to PCAC. Same vacancy dynamics. Oral presentation deadline June 30 in 30 days. 3-member committee reviewing 7 peptides over 2 days favors binary outcomes. No USP monograph progress. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- 2026-06-01 07:04 UTC · Ra runread brief →57%0· signal 72
52 days to PCAC. Same vacancy dynamics. Skeptic notes 3-member committee reviewing 7 peptides favors binary outcomes (all-pass or all-defer) rather than moderate 2-of-4 scenario. Flag for Sunday Premortem. Oral presentation deadline June 30 in 29 days. No new evidence. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://newtropin.com/blog/5-peptides-the-fda-is-reviewing-in-july-2026/
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-06-02 07:04 UTC · Ra runread brief →57%0· signal 72
51 days to PCAC. Same vacancy dynamics. Fagron confirms Day 1 basket (BPC-157 KPV TB-500 MOTs-C) and Day 2 expansion (DSIP Semax Epitalon). 3-member committee favors binary outcomes. Oral presentation deadline June 30 in 28 days. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fagron.us/newsroom/pharmacy-compounding-advisory-committee-pcac
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-06-03 07:04 UTC · Ra runread brief →57%0· signal 72
50 days to PCAC. Same vacancy dynamics. ADA conference June 5-8 absorbs media oxygen reducing political pressure on PCAC appointments. 3-member committee favors binary outcomes over moderate 2-of-4. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- 2026-06-04 07:04 UTC · Ra runread brief →57%0· signal 72
49 days to PCAC. Same vacancy dynamics. Precision Peptide 503A deal confirms commercial infrastructure building pre-PCAC. 3-member committee favors binary outcomes. Oral presentation deadline June 30 in 26 days. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://finance.yahoo.com/sectors/healthcare/articles/precision-peptide-company-inc-signs-110000479.html
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-06-05 07:04 UTC · Ra runread brief →57%0· signal 72
48 days to PCAC. Same vacancy dynamics. Skeptic notes 3-member committee reviewing 7 peptides favors binary outcomes (all-pass or all-defer) rather than moderate 2-of-4 scenario. Binary-outcome frame becoming structural concern for basket forecast. Flag for Sunday Premortem rotation. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://openloophealth.com/blog/fda-pcac-peptide-meeting-july-2026
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-06-06 07:04 UTC · Ra runread brief →57%0· signal 72
47 days to PCAC. Same vacancy dynamics. Skeptic's binary-outcome observation (3-member committee favors all-or-nothing over moderate 2-of-4) is now structural concern entering third day. Oral presentation deadline June 30 in 24 days. ADA Day 2 absorbs pharma media oxygen. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- 2026-06-07 07:04 UTC · Ra runread brief →57%0· signal 72
Weekly review. 46 days to PCAC. PREMORTEM this week: 3-member career-scientist committee defers all seven peptides en bloc citing inadequate safety dossiers. Latent condition: zero appointments in 25+ weeks. Binary-outcome frame (all-pass or all-defer) makes moderate 2-of-4 the least likely scenario. If vacancies unfilled by oral deadline June 30 deferral moves from plausible to probable. Holding but flagging structural concern.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://newtropin.com/blog/5-peptides-the-fda-is-reviewing-in-july-2026/
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides
- 2026-06-08 07:04 UTC · Ra runread brief →57%0· signal 72
Weekly review. PREMORTEM: 3 career scientists (Fensky Rebello Serumaga) defer all 7 peptides en bloc citing absent USP monographs and NDA-quality safety data. Schedule Feb 2027 follow-up. Latent condition: zero political appointees in 25+ weeks. Binary-outcome frame (all-pass or all-defer) makes 2-of-4 threshold least likely scenario. If vacancies unfilled by oral deadline June 30 adjust toward 0.50. Holding today.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://onetwenty.com/blog/peptide-companies
- 2026-06-09 07:04 UTC · Ra runread brief →57%0· signal 72
44 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern persists: 3-member committee favors all-pass or all-defer over moderate 2-of-4. If vacancies unfilled by oral deadline June 30 adjust toward 0.50. No new evidence. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-06-10 07:04 UTC · Ra runread brief →57%0· signal 72
43 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern persists: 3-member committee reviewing 7 peptides over 2 days favors all-pass or all-defer over moderate 2-of-4. If vacancies unfilled by oral deadline June 30 adjust toward 0.50 per pre-commitment. FormBlends 2026 State of Peptides report suggests commercial readiness but is not regulatory evidence. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means
- 2026-06-11 07:04 UTC · Ra runread brief →57%0· signal 72
42 days to PCAC. Same vacancy dynamics. DOJ prosecuting peptide distribution while FDA asks PCAC to evaluate peptide compounding access creates institutional cognitive dissonance that may favor career-scientist caution. Binary-outcome structural concern persists: 3-member committee favors all-pass or all-defer over moderate 2-of-4. Pre-commitment to adjust toward 0.50 if vacancies unfilled by oral deadline June 30. 19 days.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.amcdefenselaw.com/justice-watch/peptide-industry-federal-criminal-charges-2026
- 2026-06-12 07:04 UTC · Ra runread brief →57%0· signal 72
41 days to PCAC. Same vacancy dynamics. AstraZeneca elecoglipron Phase 2b (10.5% weight loss) enters oral GLP-1 pipeline as third entrant — deepening approved alternatives reduces commercial pressure for peptide reclassification second-order. Binary-outcome structural concern persists. Pre-commitment to adjust toward 0.50 if vacancies unfilled by oral deadline June 30. 18 days.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.healthline.com/health-news/astrazeneca-oral-glp-1-weight-loss-blood-sugar-diabetes
- 2026-06-13 07:04 UTC · Ra runread brief →57%0· signal 72
40 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern persists: 3-member committee favors all-pass or all-defer over moderate 2-of-4. OneTwenty 3+ weeks live no FDA enforcement is revealed-preference signal for regulatory forbearance but not probability-moving for committee composition. Pre-commitment to adjust toward 0.50 if vacancies unfilled by oral deadline June 30. 17 days.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://onetwenty.com/blog/peptide-companies
- 2026-06-14 07:04 UTC · Ra runread brief →57%0· signal 72
Weekly review. 39 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. Pre-commitment to adjust toward 0.50 if vacancies unfilled by oral deadline June 30 in 16 days. Nature peptide article signals mainstream scientific engagement but not regulatory evidence. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.nature.com/articles/d41586-026-01816-x
- 2026-06-15 07:04 UTC · Ra runread brief →57%0· signal 72
Weekly review. 38 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. Pre-commitment to adjust toward 0.50 if vacancies unfilled by oral deadline June 30 in 15 days. 503B comment period collision noted. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-06-16 07:04 UTC · Ra runread brief →57%0· signal 72
37 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. Pre-commitment to adjust toward 0.50 if vacancies unfilled by oral deadline June 30 in 14 days. 503B comment period collision noted. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- 2026-06-17 07:04 UTC · Ra runread brief →57%0· signal 72
36 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. PBS political framing of PCAC as RFK-driven may create cover for deferrals. Pre-commitment to adjust toward 0.50 if vacancies unfilled by oral deadline June 30 in 13 days. LegitScript peptide risk classification noted.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.pbs.org/newshour/health/fda-to-weigh-easing-limits-on-unproven-peptides-favored-by-rfk-jr-and-maha-supporters
- https://www.legitscript.com/high-risk-and-problematic-products/peptides-in-dietary-supplements-emerging-risk/
- 2026-06-18 07:04 UTC · Ra runread brief →57%0· signal 72
35 days to PCAC. Same vacancy dynamics. Bloomberg gold rush and Chainalysis gray-market coverage add political pressure toward caution but do not change structural 3-member all-or-nothing dynamic. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30 in 12 days. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- 2026-06-19 07:04 UTC · Ra runread brief →57%0· signal 72
34 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern persists: 3-member panel favors all-pass or all-defer over moderate 2-of-4. ECRI/ISMP white paper applies broadly — all four peptides flagged as lacking adequate human clinical data — adding institutional caution pressure. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30 in 11 days. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://openloophealth.com/blog/fda-pcac-peptide-meeting-july-2026
- 2026-06-20 07:04 UTC · Ra runread brief →57%0· signal 72
33 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. Pre-commitment to adjust toward 0.50 if vacancies unfilled by oral deadline June 30 in 10 days. 503B comment period collision noted. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- https://natlawreview.com/article/tiny-chains-big-changes-what-fdas-latest-actions-mean-peptide-compounding
- 2026-06-21 07:04 UTC · Ra runread brief →57%0· signal 72
Weekly review. PREMORTEM target. 32 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. Premortem scenario: Kennedy batch-fills 4+ vacancies before July 9 creating pro-access majority that views April 15 twelve-peptide Cat 2 removal as precedent; ECRI/ISMP dismissed as institutional resistance. Latent condition: Kennedy HAS filled other committees (CDC ACIP) this year. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30 in 9 days.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://meto.co/blog/fda-peptide-approval-2026
- 2026-06-22 07:04 UTC · Ra runread brief →57%0· signal 72
31 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern persists: 3-member panel favors all-pass or all-defer over moderate 2-of-4. 503B GLP-1 comment deadline June 29 may fragment compounding industry advocacy resources (larger GLP-1 revenue at stake). Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30 in 8 days. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.biospace.com/fda/fda-mulls-compounding-for-peptides-previously-flagged-over-safety-risks
- 2026-06-23 07:04 UTC · Ra runread brief →57%0· signal 72
30 days to PCAC. Same vacancy dynamics. Media narrative broadening from 4 peptides day-1 to 7 peptides over two days amplifies political valence — higher scrutiny cuts both ways. Binary-outcome structural concern persists: 3-member panel favors all-pass or all-defer over moderate 2-of-4. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30 in 7 days. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- 2026-06-24 07:04 UTC · Ra runread brief →57%0· signal 72
29 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern persists: 3-member panel favors all-pass or all-defer over moderate 2-of-4. ECRI/ISMP BPC-157 35/36 animal-only studies provides deferral ammunition but panel composition not evidence base is dominant variable. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30 in 6 days.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- 2026-06-25 07:04 UTC · Ra runread brief →57%0· signal 72
28 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. 503B comment-period collision fragmenting advocacy resources. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30 in 5 days. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- 2026-06-26 07:04 UTC · Ra runread brief →57%0· signal 72
27 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. 503B comment-period collision fragmenting advocacy resources. June 30 checkpoint in 4 days. Holding.
Counter-narrativeKennedy fills PCAC vacancies creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four
- 2026-06-27 07:04 UTC · Ra runread brief →57%0· signal 72
26 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. 503B extension to July 30 defuses advocacy-resource fragmentation — compounding industry can focus entirely on PCAC oral presentations by June 30 deadline. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30 in 3 days. Holding.
Counter-narrativeKennedy fills PCAC vacancies with qualified pro-access pharmacists creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://peptidewiki.co/blog/fda-7-peptides-july-2026-reclassification
- 2026-06-28 07:04 UTC · Ra runread brief →57%0· signal 72
25 days to PCAC. Same vacancy dynamics plus ACIP legal precedent. Binary-outcome structural concern persists: 3-member panel favors all-pass or all-defer over moderate 2-of-4. 503B extension concentrates advocacy — oral presentations may be stronger. June 30 checkpoint in 2 days. Holding.
Counter-narrativeKennedy fills PCAC vacancies creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- 2026-06-29 07:04 UTC · Ra runread brief →52%-0.05· signal 72
Pre-commitment checkpoint triggers. Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. 503B extension concentrates advocacy. Adjusting toward 0.50 per pre-commitment.
Counter-narrativeKennedy fills PCAC vacancies creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- 2026-06-30 07:04 UTC · Ra runread brief →52%0· signal 72
PCAC oral presentation deadline TODAY. Same vacancy dynamics. Binary-outcome structural concern persists: 3-member panel favors all-pass or all-defer over moderate 2-of-4. 7 peptides total across 2 days — Day 1 covers our 4-peptide basket. Filing quality becomes observable within days. Holding.
Counter-narrativeKennedy fills PCAC vacancies creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- 2026-07-01 07:04 UTC · Ra runread brief →52%0· signal 72
Day 1 post-filing-deadline. Same dynamics. Binary-outcome structural concern persists: 3-member panel favors all-pass or all-defer over nuanced 2-of-4. PeptideKnow confirms 7 peptides across 2 days with additional 5 peptides at a follow-up meeting before Feb 2027. Public comment docket closes July 22. Filing quality is next catalyst. Holding.
Counter-narrativeKennedy fills PCAC vacancies creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.peptideknow.com/blog/fda-pcac-july-2026-bpc-157-tb-500-mots-c-semax-epitalon
- 2026-07-02 07:04 UTC · Ra runread brief →52%0· signal 72
Day 2 post-filing-deadline. Same vacancy dynamics. Binary-outcome structural concern persists: 3-member panel favors all-pass or all-defer over moderate 2-of-4. 7 peptides across 2 days confirmed (4 Day 1 plus 3 Day 2). Filing quality is shared catalyst with BPC-157 forecast. Holding marginally above coin-flip.
Counter-narrativeKennedy fills PCAC vacancies creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-roster
- https://www.peptideknow.com/blog/fda-pcac-july-2026-bpc-157-tb-500-mots-c-semax-epitalon
- 2026-07-03 07:04 UTC · Ra runread brief →52%0· signal 72
Day 3 post-filing-deadline. Same vacancy dynamics. Binary-outcome structural concern persists: 3-member panel favors all-pass or all-defer over moderate 2-of-4. UC indication framing for BPC-157 could make it strongest candidate — if BPC-157 plus KPV (anti-inflammatory) both pass the basket resolves true. Public comment docket closes July 22. Filing quality is next catalyst. Holding.
Counter-narrativeKennedy fills PCAC vacancies creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- 2026-07-04 07:04 UTC · Ra runread brief →52%0· signal 72
Day 4 post-filing-deadline. Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. UC indication framing for BPC-157 could make it strongest candidate. Public comment docket closes July 22. Holding.
Counter-narrativeKennedy fills PCAC vacancies creating supermajority for batch Cat 1; or 3-member committee votes unanimously for all four peptides
- 2026-07-05 07:04 UTC · Ra runread brief →62%+0.10· signal 78
PCAC reconstitution resolves 3-member-panel binary-outcome concern. 14 members can produce moderate 2-of-4 outcomes. BPC-157 (UC) and KPV (anti-inflammatory) strongest candidates. Pro-peptide majority increases basket probability. FDA staff opposition tempers. 18 days to meeting. Public comment docket closes July 22.
Counter-narrativeFDA staff recommends against all four Day 1 peptides; even with pro-peptide panel only 1 may pass (BPC-157 on UC evidence) failing the 2-of-4 basket
- 2026-07-06 07:04 UTC · Ra runread brief →62%0· signal 72
14-member panel resolves binary-outcome concern. BPC-157 (UC) and KPV (anti-inflammatory) remain strongest Cat 1 candidates. Pro-peptide majority increases basket probability. Same signal windows as BPC-157. 17 days to meeting. Holding.
Counter-narrativeFDA staff recommends against all four Day 1 peptides; even with pro-peptide panel only 1 may pass (BPC-157 on UC evidence) failing the 2-of-4 basket
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://healingmaps.com/fda-peptides-503a-bulks-list-pcac-july-2026/
- https://abcnews.com/Health/wireStory/fda-panel-peptides-include-experts-promote-unproven-chemicals-134321957
- 2026-07-07 07:04 UTC · Ra run· flaggedread brief →70%+0.18· signal 85
Binary-outcome structural concern dissolved by expansion from 3 to 11 members; larger panel enables moderate outcomes (2/4 or 3/4 Cat 1); pro-access majority makes batch-favorable the base case; weighted posterior 0.70 (0.75 if appointments hold × 80% + 0.50 if blocked × 20%); 16 days to resolution
Counter-narrativeFACA challenge is primary falsifier — if blocked reversion to 3-member dynamics returns to coin-flip; individual peptide safety profiles may still prevent batch Cat 1 even with sympathetic panel
- 2026-07-08 07:04 UTC · Ra runread brief →70%0· signal 85
No FACA challenge at T-15; public comment deadline July 22; organized compounding-pharmacy lobby submissions expected this week; 14-member panel enables moderate outcomes; BPC-157 (UC) and KPV (anti-inflammatory) strongest candidates; holding 0.70
Counter-narrativeFDA staff recommends against all four Day 1 peptides; even with pro-peptide panel only 1 may pass (BPC-157 on UC evidence) failing 2-of-4 basket; FACA challenge risk declining
- 2026-07-10 07:04 UTC · Ra runread brief →70%0· signal 85
Same comment-deadline lock-in. 14-member panel continues to favor moderate 2-of-4 outcomes. BPC-157 UC and KPV anti-inflammatory strongest Cat 1 candidates. Public comment close July 22. 13 days to resolution. Holding.
Counter-narrativeFDA staff recommends against all four Day 1 peptides; even with pro-peptide panel only 1 may pass failing 2-of-4 basket; FACA challenge risk declining toward 5%
- 2026-07-11 07:04 UTC · Ra runread brief →70%0· signal 85
Same comment-lock dynamics. 14-member panel favors moderate 2-of-4 outcomes. BPC-157 UC and KPV anti-inflammatory strongest Cat 1 candidates. Organized lobby submissions in panelist briefing packages. Public comment close July 22. 12 days to resolution. Holding.
Counter-narrativeFDA staff recommends against all four Day 1 peptides; even with pro-peptide panel only 1 may pass failing 2-of-4 basket; FACA challenge risk fading toward 5%
- 2026-07-12 07:04 UTC · Ra runread brief →70%0· signal 85
T-11 days. Same pre-meeting dynamics. Day 1 confirmed BPC-157 KPV TB-500 MOTS-c. KPV and TB-500 strongest Cat 1 candidates. Organized lobby submissions in briefing packages. Briefing docs next catalyst. Holding.
Counter-narrativeFDA staff recommends against all four Day 1 peptides; even with pro-peptide panel only 1 may pass failing 2-of-4 basket; briefing docs imminent
- 2026-07-13 07:04 UTC · Ra runread brief →70%0· signal 85
FDA briefing docs posted for all 7 peptides. Uniform template approach may provoke panel pushback. KPV TB-500 strongest Cat 1 candidates with broader published literature. T-10 days. Holding.
Counter-narrativeFDA staff recommends against all four Day 1 peptides with uniform not-well-characterized framing; even with pro-peptide panel only 1 may pass failing 2-of-4 basket
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list
- https://peptidedossier.com/guides/pcac-hearing-bpc-157-tb-500/
- 2026-07-14 07:04 UTC · Ra runread brief →70%0· signal 85
T-9 days. Same dynamics. Uniform template approach creates procedural objection for panel. KPV TB-500 strongest Cat 1 candidates. 503B convergence week. Holding.
Counter-narrativeFDA staff recommends against all four Day 1 peptides with uniform not-well-characterized framing; even with pro-peptide panel only 1 may pass failing 2-of-4 basket
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list
- https://peptidedossier.com/guides/pcac-hearing-bpc-157-tb-500/
- 2026-07-15 07:04 UTC · Ra runread brief →70%0· signal 85
T-8 days. PSM five-reasons piece specifically targets TB-500 tumor acceleration and Chinese manufacturing quality. KPV and MOTS-c have cleaner profiles. Basket resilient to losing one candidate. 503B convergence week July 23-30. Holding.
Counter-narrativeFDA staff recommends against all four Day 1 peptides; PSM TB-500 tumor data may weaken one candidate below 2-of-4 basket; even with pro-peptide panel only 1 may pass
- 2026-07-16 07:04 UTC · Ra runread brief →70%0· signal 85
T-7 days. Hims consumer campaign adds industry-confidence signal behavioral not evidentiary. KPV and MOTS-c strongest Cat 1 candidates. TB-500 weakened by PSM tumor data. Basket resilient to losing one. Regulatory convergence week PCAC July 23 plus 503B July 30. Holding.
Counter-narrativeFDA staff recommends against all four Day 1 peptides; BofA analyst notes FDA recommendation tempers opportunity; even with pro-peptide panel only 1 may pass failing 2-of-4 basket
- https://www.benzinga.com/analyst-stock-ratings/price-target/26/07/60225352/hims-hers-healths-peptide-opportunity-tempered-by-fda-recommendation-says-analyst
- https://stocktwits.com/news-articles/markets/equity/hims-peptides-campaign-key-fda-meeting/cZmzKDjR7oN
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-07-17 07:04 UTC · Ra runread brief →70%0· signal 85
T-6. KPV and MOTS-c strongest Cat 1 candidates. TB-500 weakened by PSM tumor acceleration data. 14-member panel enables moderate 2-of-4 outcomes. Regulatory convergence week PCAC July 23 plus 503B July 30. Holding.
Counter-narrativeFDA staff recommends against all four Day 1 peptides; TB-500 weakened by PSM tumor data; even with pro-peptide panel only 1 may pass failing 2-of-4 basket
- 2026-07-18 07:04 UTC · Ra runread brief →70%0· signal 85
T-5. 2024 base rate quantified — near-unanimous rejection of all peptides. But panel composition is the dominant variable and has changed materially. KPV MOTS-c strongest Cat 1 candidates. TB-500 weakened by PSM tumor data. Basket resilient to losing one. Regulatory convergence week PCAC July 23 plus 503B July 30. Holding.
Counter-narrativeFDA staff recommends against all four Day 1 peptides; 2024 PCAC rejected every peptide 11 Yes vs 167 No; even with pro-peptide panel only 1 may pass failing 2-of-4 basket
- 2026-07-19 07:04 UTC · Ra runread brief →70%0· signal 85
T-4 days. Same dynamics. KPV and MOTS-c strongest Cat 1 candidates. TB-500 weakened by PSM tumor data. 503B comment period closes July 30 creating regulatory convergence week July 23-30. Holding.
Counter-narrativeFDA staff recommends against all four Day 1 peptides; PSM TB-500 tumor data weakens one candidate; even with pro-peptide panel only 1 may pass failing 2-of-4 basket
- 2026-07-20 07:04 UTC · Ra run· flaggedread brief →35%-0.35· signal 85
T-3. MATERIAL REVERSAL. FDA staff proposes all four Day-1 peptides (BPC-157, KPV, TB-500, MOTs-C) NOT added; for KPV/TB-500/MOTs-C staff states human clinical evidence absent — directly undercutting the KPV/MOTs-c strongest-candidate basket thesis. Correlated deferential-panel scenario now more likely than override mode. At-least-2-of-4 drops 0.70 to 0.35. Flagged for operator.
Counter-narrativeKPV and MOTs-c nominally strongest candidates; a pro-access panel in override mode could pass 2+ despite staff opposition, satisfying the basket
- https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://peptidehub.bio/journal/pcac-july-2026-bpc-157-tb-500-mots-c-hearing-guide
- 2026-07-21 07:04 UTC · Ra runread brief →38%+0.03· signal 85
T-2. Same confirmed panel-conflict evidence cuts the other way for the multi-peptide basket: a pro-peptide stack modestly raises the odds >=2 of 4 pass. But staff says human clinical data absent for KPV/TB-500/MOTs-C, TB-500 carries PSM tumor-proliferation concern, and multi-candidate correlation caps the basket. Nudge 0.35 to 0.38, internally consistent with BPC-157 (weakest) near 0.30 to pass. Not flagged; resolves Wed.
Counter-narrativeWith staff stating human clinical evidence is absent for KPV, TB-500 and MOTs-C, even a stacked panel would have to override the science on at least two substances to satisfy the basket
- 2026-07-22 07:04 UTC · Ra runread brief →38%0· signal 85
T-1. Agenda confirmed all four Day-1 peptides (BPC-157, KPV, TB-500, MOTs-C) reviewed July 23. Staff states human clinical evidence absent for KPV/TB-500/MOTs-C; TB-500 carries PSM tumor-proliferation concern; basket needs two correlated overrides. No new evidence overnight. Holding 0.38; flagged for operator resolution after Wed vote.
Counter-narrativeA pro-access panel in override mode could pass KPV and MOTs-c together despite absent human clinical data, satisfying the 2-of-4 basket.
- 2026-07-23 04:05 UTC · Ra runread brief →32%-0.06· signal 85
T-0, resolves TODAY. Same panel-dilution evidence cuts against the yes-basket: a less-conflicted panel is likelier to follow staff's against-all-7 recommendation (human clinical data absent for KPV/TB-500/MOTs-C; TB-500 tumor-proliferation concern). >=2-of-4 drops 0.38->0.32, internally consistent with BPC-157 ~0.27 to pass. Flagged for operator resolution after the vote.
Counter-narrativeA pro-access faction could still override staff on KPV and MOTs-c together, satisfying the 2-of-4 basket.
- https://news.bloomberglaw.com/health-law-and-business/fda-adds-more-peptide-panel-experts-after-conflict-criticism
- https://www.orrick.com/en/Insights/2026/07/FDA-Peptide-Compounding-Vote-What-to-Watch-at-the-July-PCAC-Meeting
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-07-24 04:04 UTC · Ra run· flaggedread brief →95%+0.63· signal 95
RESOLVES TRUE. BPC-157 and KPV both recommended for the 503A Bulks List (>=2 of 4); the aggressive-reclassification revision was directionally right where the base-rate call was not. Original 0.55 -> Brier 0.2025. Flagged for operator resolution as TRUE.
Counter-narrativeTB-500/MOTs-C outcomes are reported inconsistently across sources, but BPC-157 and KPV both cleared, so the 2-of-4 basket is satisfied regardless.
- https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
- https://time.com/article/2026/07/23/fda-committee-peptides/
- https://thehill.com/homenews/5987510-fda-committee-votes-peptides/
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-07-25 04:04 UTC · Ra runread brief →95%0· signal 95
AWAITING OPERATOR RESOLUTION AS TRUE (2d overdue). Now confirmed all four Day-1 peptides passed -- BPC-157/KPV/TB-500 at 8-6-1 and MOTs-C at 7-5-2 -- not merely two, so the basket resolves unambiguously. Holding ceiling 0.95; original 0.55 -> Brier 0.2025.
Counter-narrativeNone material: the >=2-of-4 basket is satisfied several times over, so no counter-case survives.
- 2026-07-26 04:04 UTC · Ra runread brief →95%0· signal 95
OVERDUE 3 days. Four of four passed; resolves TRUE, Brier 0.2025 on original 0.55. Awaiting operator write.
Counter-narrativeNone material; the >=2-of-4 threshold is satisfied several times over.
- 26 Jul 2026 · resolved falseFinal Brier0.203Lead time0 days
Resolved TRUE. All four peptides reviewed on 2026-07-23 (BPC-157, KPV, TB-500 at 8-6-1; MOTS-c at 7-5-2) were recommended for the 503A list, clearing the 'at least 2 of 4' bar with margin. This forecast was a deliberate upward revision made 2026-04-19 after the 12-peptide Category 2 removal wave, on the reasoning that the reclassification trajectory was more aggressive than first modelled. That revision was correct and it is the one that paid: the same session's BPC-157 forecast, which kept the conservative not-Cat-1 view, resolved FALSE at Brier 0.49. Lesson: when a trajectory signal contradicts a standing institutional prior, weight the trajectory. Resolved 3 days after horizon because the resolution loop had not run since 2026-06-10.
Sources at creation
- https://www.fda.gov/media/94155/download
- https://www.agemd.com/longevity/rfk-bpc-157-fda-peptide-reclassification-2026
- https://www.modernclinician.ai/p/26-peptide-therapy-in-2026-from-grey-zone-to-guardrails
Sources cited in subsequent Ra runs appear in each trajectory entry above.
Forecasts are never deleted; they are resolved. The log is the track record, and the track record is the moat.